2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-110192
    ML 297 1443246-62-5 99.14%
    ML 297 (VU 0456810) is a potent and selective GIRK1/2 activator, with an EC50 of 0.16 μM. ML 297 is potential for the treatment of epilepsy.
    ML 297
  • HY-112173
    Prolylleucine 61596-47-2 99.85%
    Prolylleucine is a dipeptide containing branched-chain amino acids. Prolylleucine can affect the circadian rhythms and behaviour of animals.
    Prolylleucine
  • HY-113093
    Ethyl glucuronide 17685-04-0 ≥98.0%
    Ethyl glucuronide is an endogenous metabolite. Ethyl glucuronide is the metabolite of ethanol. Ethyl glucuronide is a biomarker for ethanol exposure that accumulates in hair and reflects the alcohol intake over a time period. Ethyl glucuronide is the agonist for TLR4.
    Ethyl glucuronide
  • HY-113289
    Brassicasterol 474-67-9 98.71%
    Brassicasterol is a metabolite of Ergosterol and has cardiovascular protective effects. Brassicasterol exerts anticancer effects in prostate cancer through dual targeting of AKT and androgen receptor signaling pathways. Brassicasterol inhibits HSV-1 (IC50=1.2 μM) and Mycobacterium tuberculosis. Brassicasterol also inhibits sterol δ 24-reductase, slowing the progression of atherosclerosis. Brassicasterol is also a cerebrospinal fluid biomarker for Alzheimer's disease.
    Brassicasterol
  • HY-116461
    ML-184 794572-10-4 99.57%
    ML-184 (CID244033) is a selective GPR55 agonist with an EC50 of 250 nM, more than 100-fold selectivity for GPR55 over GPR35, CB1, and CB2. ML-184 induces ERK1/2 phosphorylation and PKCβII translocation to the plasma membrane via activation of GPR55. ML-184 (CID2440433) increases the proliferation of neural stem cells and promotes neuronal differentiation in vitro.
    ML-184
  • HY-118467
    Benzolamide 3368-13-6 99.07%
    Benzolamide (CL11366) is a potent carbonic anhydrase (CA) inhibitor, with Kis of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a Ki of 54 nM. Benzolamide can be used for the research of glaucoma and seizures.
    Benzolamide
  • HY-124475
    Antalarmin 157284-96-3 99.95%
    Antalarmin is a selective nonpeptide corticotropin-releasing factor receptor 1 (CRHR1) antagonist with a Ki of 2.7 nM. Antalarmin can pass through the blood–brain barrier.
    Antalarmin
  • HY-126429
    Nav1.1 activator 1 2332897-85-3 98.98%
    Nav1.1 activator 1 (compound 4), a highly potent Nav1.1 activator with BBB penetration, increases decay time constant (tau) of Nav1.1 currents at 0.03 μM along with significant selectivity against Nav1.2, Nav1.5, and Nav1.6.
    Nav1.1 activator 1
  • HY-128057
    NCRW0005-F05 342779-66-2 ≥99.0%
    NCRW0005-F05 is a potent GPR139 antagonist with an IC50 value of 0.21 μM. NCRW0005-F05 can be used to research diabetes, obesity and Parkinson's disease.
    NCRW0005-F05
  • HY-128121
    MLS1547 315698-36-3 99.94%
    MLS1547 is a highly efficacious G protein-biased dopamine D2 receptor (D2R) agonist (Ki=1.2 μM). MLS1547 stimulates D2R G protein-mediated signaling (EC50=0.37 μM in a calcium mobilization assay). MLS1547 acts as an antagonist for dopamine (DA)-stimulated β-arrestin recruitment to the D2R (IC50=9.9 μM).
    MLS1547
  • HY-133708
    β-Glucogallin 13405-60-2
    β-Glucogallin is an orally active and selective aldose reductase (AKR1B1) inhibitor with an IC50 value of 58 μM when using Glyceraldehyde (HY-128748) as AKR1B1 substrate. β-Glucogallin reduces ROS, PDGF, RAGE, and NF-κB. β-Glucogallin increases SOD. β-Glucogallin has antioxidant and hepatoprotective effects. β-Glucogallin can be used in retinal research.
    β-Glucogallin
  • HY-136311
    NCT-504 1222765-97-0 ≥98.0%
    NCT-504 is a selective allosteric inhibitor of PIP4Kγ, with an IC50 of 15.8 μM. NCT-504 is potential for the research of Huntington's disease.
    NCT-504
  • HY-138559
    GW604714X 853953-65-8 98.49%
    GW604714X is a potent inhibitor of mitochondrial respiration supported by pyruvate but not other substrates. GW604714X is a highly specific mitochondrial pyruvate carrier (MPC) inhibitor with a Ki <0.1 nM. GW604714X also inhibits L-lactate transport by the plasma membrane monocarboxylate transporter (MCT1), but at concentrations more than 4 orders of magnitude greater than the MPC.
    GW604714X
  • HY-14316A
    Tebanicline dihydrochloride 209326-19-2 ≥98.0%
    Tebanicline dihydrochloride (Ebanicline dihydrochloride) is a nAChR modulator with potent, orally effective analgesic activity. It inhibits the binding of cytisine to α4β2 neuronal nAChRs with a Ki of 37 pM.
    Tebanicline dihydrochloride
  • HY-145628
    CM398 1121931-70-1 99.85%
    CM398 is a highly selective, orally active sigma-2 receptor ligand (Ki=0.43 nM), with high sigma-1/sigma-2 selectivity rato (1000-fold). CM398 shows notable affinity for dopamine (Ki=32.90 nM) and serotonin transporters (Ki=244.2 nM). CM398 shows promising anti-inflammatory analgesic effects in the formalin model of inflammatory pain in mice.
    CM398
  • HY-16637D
    Folic acid disodium 29704-76-5 99.15%
    Folic acid disodium (Vitamin B9 disodium; Vitamin M disodium) is an orally active disodium salt form of Folic acid (HY-16637) with an intrinsic dissolution rate (IDR) of 4.96·105 g/s. Folic acid disodium serves as cofactor in single-carbon transfer reactions and exhibits protective effects against neural tube defects, ischemic events, and cancer. Folate acid disodium overload leads to impaired brain development in embryogenesis and promotes growth of precancerous altered cells. Folic acid deficiency leads to megaloblastic anemia.
    Folic acid disodium
  • HY-16728B
    Rapastinel Trifluoroacetate 1435786-04-1 ≥98.0%
    Rapastinel Trifluoroacetate (GLYX-13 Trifluoroacetate) is an NMDA receptor modulator with glycine-site partial agonist properties. Rapastinel Trifluoroacetate has the potential for major depressive disorder treatment.
    Rapastinel Trifluoroacetate
  • HY-A0019A
    Paliperidone palmitate 199739-10-1 98.92%
    Paliperidone palmitate is an orally effective competitive antagonist of dopamine D2 receptors and 5-hydroxytryptamine 2A (5-HT2A) receptors that can cross the blood-brain barrier. Paliperidone palmitate competitively inhibits the effects of dopamine and 5-hydroxytryptamine by binding to dopamine D2 receptors and 5-HT2A receptors, regulating the balance of the neurotransmitter system and thus exerting antipsychotic activity. Paliperidone palmitate is mainly used in the research field of schizophrenia.
    Paliperidone palmitate
  • HY-B0071A
    Granisetron Hydrochloride 107007-99-8 99.87%
    Granisetron (Hydrochloride) (BRL 43694A) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy.
    Granisetron Hydrochloride
  • HY-P10638
    TAT-CN21 99.90%
    TatCN21 is a potent and selective inhibitor peptide for the calcium/calmodulin-dependent protein kinase II (CaMKII), a ubiquitously-expressed multifunctional serine/threonine protein kinase, with an IC50 of 77 nM. TatCN21 can be utilized in research on ischemia and neurodegenerative diseases.
    TAT-CN21
Cat. No. Product Name / Synonyms Application Reactivity